RXST vs TMDX vs ATRC vs NVCR

For growth investors, TransMedics Group, Inc.

(TMDX) is the stronger pick with 37. 1% revenue growth year-over-year, versus -3. 9% for RxSight, Inc. (RXST). TransMedics Group, Inc. (TMDX) offers the better valuation at 15. 0x trailing P/E (29. 9x forward), making it the more compelling value choice. Analysts rate TransMedics Group, Inc. (TMDX) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, TransMedics Group, Inc.

is actually cheaper at 29. 9x.

Over the past 5 years, TransMedics Group, Inc.

(TMDX) delivered a total return of +200. 7%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: TMDX returned +226. 0% versus RXST's -63. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AtriCure, Inc.

(ATRC) is the lower-risk stock at 1. 03β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 115% more volatile than ATRC relative to the S&P 500. On balance sheet safety, RxSight, Inc. (RXST) carries a lower debt/equity ratio of 4% versus 99% for TransMedics Group, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TransMedics Group, Inc.

(TMDX) is pulling ahead at 37. 1% versus -3. 9% for RxSight, Inc. (RXST). On earnings-per-share growth, the picture is similar: TransMedics Group, Inc. grew EPS 382. 2% year-over-year, compared to -33. 8% for RxSight, Inc.. Over a 3-year CAGR, TMDX leads at 86. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TransMedics Group, Inc.

(TMDX) is the more profitable company, earning 31. 4% net margin versus -29. 0% for RxSight, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMDX leads at 17. 9% versus -35. 8% for RXST. At the gross margin level — before operating expenses — RXST leads at 76. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, TransMedics Group, Inc.

(TMDX) trades at 29. 9x forward P/E versus 370. 7x for AtriCure, Inc. — 340. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, AtriCure, Inc.

(ATRC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03)). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ATRC: +95. 1%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RXST is a small-cap quality compounder stock; TMDX is a small-cap high-growth stock; ATRC is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.